Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bluetongue virus serotype 8 (BTV-8) is a double-stranded RNA virus belonging to the genus Orbivirus within the family Reoviridae, and it is the causative agent of bluetongue disease in ruminants [1, 3]. The virus is non-enveloped and features a segmented genome encoding seven structural proteins (VP1–VP7) and several non-structural proteins (NS1–NS4), with the outer capsid protein VP2 serving as the primary determinant of serotype specificity and the main target for neutralizing antibodies [5, 7]. BTV-8 gained significant attention following its unprecedented emergence in Northern Europe in 2006, where it demonstrated high pathogenicity in cattle and the ability for transplacental transmission, leading to severe economic impacts [1, 8]. The biological function of the virus involves complex processes of cell attachment, entry via endocytosis, and replication within viral inclusion bodies in the host cytoplasm [5, 17]. Therapeutic strategies primarily focus on prevention through the use of inactivated vaccines, such as BLUEVAC BTV8 and BTVPUR AlSap 8, which stimulate active immunity to prevent viremia and reduce clinical signs [4, 12]. These vaccines are essential for controlling outbreaks, although their efficacy is largely serotype-specific, posing challenges in regions where multiple BTV serotypes co-circulate [10, 14].
Active immunization to induce neutralizing antibodies and cellular immunity against viral proteins to prevent infection and viremia
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bluetongue virus serotype 8 (BTV-8) (BTV-8).